The FDA told Novo Nordisk in a Feb. 5 letter that a TV commercial for its Wegovy pill is "false or misleading." Regulators said the ad implies the pill is an improvement over other GLP-1 drugs and that slogans like "live lighter" and "a way forward" suggest additional weight loss and unproven emotional benefits. The FDA found the advertisement violated the Federal Food, Drug, and Cosmetic Act and asked Novo to take immediate corrective action.
FDA Calls Novo Nordisk TV Ad For Wegovy Pill 'False Or Misleading' — Regulators Seek Immediate Fix
FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo
The U.S. Food and Drug Administration has told Novo Nordisk that a television advertisement for its weight-loss pill is "false or misleading," according to a letter dated Feb. 5.
What the FDA said
The agency said the commercial creates the misleading impression that Wegovy in pill form represents an advancement or improvement over other weight-loss medicines in the GLP-1 drug class. It specifically flagged taglines such as "live lighter" and "a way forward" as implying additional weight loss compared with other currently approved GLP-1 treatments — a benefit the FDA says has not been demonstrated.
"Additionally, they misleadingly imply benefits beyond physical weight loss, such as emotional relief, reduced psychological burden, hope, or direction for patients' lives," the agency wrote, noting these broader life benefits are not supported by evidence.
The FDA determined the advertisement violated the Federal Food, Drug, and Cosmetic Act and asked Novo Nordisk to take immediate action to remedy any violations.
The Danish drugmaker did not immediately respond to Reuters' request for comment, according to the letter.
Why it matters
The ruling underscores regulators' scrutiny of how pharmaceutical products are marketed, especially in the competitive market for GLP-1 treatments for weight management. Claims that a medicine offers superior weight-loss results or life-changing emotional benefits require strong evidence; otherwise, regulators can require corrections or removal of the advertising.
(Reporting by Sriparna Roy in Bengaluru; Editing by Vijay Kishore)
Help us improve.
